FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ludy Lutgens

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Co-author Network

Publications

TOP 3
Remi A Nout; Natalja T Ter Haar; Elzbieta M Van der Steen-Banasik; Ronald van Eijk; Tjalling Bosse; Carien L Creutzberg; Jan J Jobsen; Ina M Jürgenliemk-Schulz; Ludy C H W Lutgens; Vincent T H B M Smit
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
Remi A Nout; Hein Putter; Annerie Slot; Marika C Stenfert Kroese; Lonneke V van de Poll-Franse; Elzbieta M Van der Steen-Banasik; Jan J Jobsen; Ina M Jürgenliemk-Schulz; Ludy C H W Lutgens; Jan Willem M Mens; Hans W Nijman; Carien L Creutzberg
Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.
Carien L Creutzberg; Jan J Jobsen; Ludy C H W Lutgens; Marnix L M Lybeert; Jan-Willem M Mens; Remi A Nout; Elisabeth Pras; Lonneke V van de Poll-Franse; Wim L J van Putten; Carla C Wárlám-Rodenhuis
Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ludy Lutgens (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Remi A Nout; Natalja T Ter Haar; Elzbieta M Van der Steen-Banasik; Ronald van Eijk; Tjalling Bosse; Carien L Creutzberg; Jan J Jobsen; Ina M Jürgenliemk-Schulz; Ludy C H W Lutgens; Vincent T H B M Smit
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
Gynecologic oncology 2012;126(3):466-73.
2012: Remi A Nout; Hein Putter; Annerie Slot; Marika C Stenfert Kroese; Lonneke V van de Poll-Franse; Elzbieta M Van der Steen-Banasik; Jan J Jobsen; Ina M Jürgenliemk-Schulz; Ludy C H W Lutgens; Jan Willem M Mens; Hans W Nijman; Carien L Creutzberg
Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.
European journal of cancer (Oxford, England : 1990) 2012;48(11):1638-48.
2011: Carien L Creutzberg; Jan J Jobsen; Ludy C H W Lutgens; Marnix L M Lybeert; Jan-Willem M Mens; Remi A Nout; Elisabeth Pras; Lonneke V van de Poll-Franse; Wim L J van Putten; Carla C Wárlám-Rodenhuis
Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.
International journal of radiation oncology, biology, physics 2011;81(4):e631-8.
2011: Remi A Nout; Lonneke V van de Poll-Franse; Marnix L M Lybeert; Carla C Wárlám-Rodenhuis; Jan J Jobsen; Jan Willem M Mens; Ludy C H W Lutgens; Betty Pras; Wim L J van Putten; Carien L Creutzberg
Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1692-700.
2010: R A Nout; Vincent T H B M Smit; Hein Putter; Ina M Jürgenliemk-Schulz; Jan J Jobsen; Ludy C H W Lutgens; Elzbieta M Van der Steen-Banasik; J W M Mens; Annerie Slot; M C Stenfert Kroese; B N F M van Bunningen; A C Ansink; Wim L J van Putten; Carien L Creutzberg
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Lancet 2010;375(9717):816-23.
2010: Pataje G S Prasanna; William F Blakely; Jean-Marc Bertho; John P Chute; Eric P Cohen; Ronald E Goans; Marcy B Grace; Patricia K Lillis-Hearne; David C Lloyd; Ludy C H W Lutgens; Viktor Meineke; Natalia I Ossetrova; Alex Romanyukha; Julie Saba; Daniel J Weisdorf; Andrzej Wojcik; Eduardo G Yukihara; Terry Pellmar
Synopsis of partial-body radiation diagnostic biomarkers and medical management of radiation injury workshop.
Radiation research 2010;173(2):245-53.
2009: Remi A Nout; Hein Putter; Ina M Jürgenliemk-Schulz; Jan J Jobsen; Ludy C H W Lutgens; Elzbieta M Van der Steen-Banasik; Jan Willem M Mens; Annerie Slot; Marika C Stenfert Kroese; Bart N F M van Bunningen; Vincent T H B M Smit; Hans W Nijman; Philine P van den Tol; Carien L Creutzberg
Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3547-56.
2007: Ludy C H W Lutgens; Philippe Lambin
Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline.
World journal of gastroenterology : WJG 2007;13(22):3033-42.
2007: Francesca De Lorenzi; Hanneke J P Tielemans; René R W J van der Hulst; Rose Rhemrev; Fred H M Nieman; Ludy C H W Lutgens; Willy D Boeckx
Is the treatment of keloid scars still a challenge in 2006?
Annals of plastic surgery 2007;58(2):186-92.
2006: Dirk De Ruysscher; Madelon Pijls-Johannesma; Søren M Bentzen; Andre Minken; Rinus Wanders; Ludy C H W Lutgens; Monique Hochstenbag; Liesbeth J Boersma; Bradly G Wouters; Guido Lammering; Johan Vansteenkiste; Philippe Lambin
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1057-63.
2005: Ariane Vanclée; Ludy C H W Lutgens; Ellis B H Oving; Nicolaas E P Deutz; Marion J J Gijbels; Harry C Schouten; Gerard M J Bos
Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
Bone marrow transplantation 2005;36(10):907-15.
2005: Astrid N Scholten; Wim L J van Putten; Henk Beerman; Vincent T H B M Smit; Peter C M Koper; Marnix L M Lybeert; Jan J Jobsen; Carla C Wárlám-Rodenhuis; Karin A J De Winter; Ludy C H W Lutgens; Mat van Lent; Carien L Creutzberg
Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review.
International journal of radiation oncology, biology, physics 2005;63(3):834-8.
2005: Antoinet van Der Wel; S M J J G Nijsten; Monique Hochstenbag; Rob Lamers; Liesbeth J Boersma; Rinus Wanders; Ludy C H W Lutgens; Michael Zimny; Søren M Bentzen; Bradly G Wouters; Philippe Lambin; Dirk De Ruysscher
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
International journal of radiation oncology, biology, physics 2005;61(3):649-55.
2005: Ludy C H W Lutgens; N M A Blijlevens; Nicolaas E P Deutz; J Peter Donnelly; Philippe Lambin; Ben E de Pauw
Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests.
Cancer 2005;103(1):191-9.
2004: Ludy C H W Lutgens; Nicolaas E P Deutz; Marlies Granzier-Peeters; Regina Beets-Tan; Dirk De Ruysscher; John Gueulette; Jack P M Cleutjens; Martijn Berger; Bradly G Wouters; Maarten F von Meyenfeldt; Philippe Lambin
Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients.
International journal of radiation oncology, biology, physics 2004;60(1):275-85.
2004: N M A Blijlevens; Ludy C H W Lutgens; A V M B Schattenberg; J Peter Donnelly
Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy.
Bone marrow transplantation 2004;34(3):193-6.
2004: Carien L Creutzberg; Wim L J van Putten; Carla C Wárlám-Rodenhuis; Alfons C M van den Bergh; Karin A J De Winter; Peter C M Koper; Marnix L M Lybeert; Annerie Slot; Ludy C H W Lutgens; Marika C Stenfert Kroese; Henk Beerman; Mat van Lent
Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1234-41.
2003: Ludy C H W Lutgens; Nicolaas E P Deutz; John Gueulette; Jack P M Cleutjens; Martijn P F Berger; Bradly G Wouters; Maarten F von Meyenfeldt; Philippe Lambin
Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage.
International journal of radiation oncology, biology, physics 2003;57(4):1067-74.
2003: Carien L Creutzberg; Wim L J van Putten; Peter C M Koper; Marnix L M Lybeert; Jan J Jobsen; Carla C Wárlám-Rodenhuis; Karin A J De Winter; Ludy C H W Lutgens; Alfons C M van den Bergh; Elzbieta van der Steen-Banasik; Henk Beerman; Mat van Lent
Survival after relapse in patients with endometrial cancer: results from a randomized trial.
Gynecologic oncology 2003;89(2):201-9.
2002: Janneke M de Rijke; H W H M van der Putten; Ludy C H W Lutgens; A C Voogd; Roy F P M Kruitwagen; J A A M van Dijck; Leo J Schouten
Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996.
European journal of cancer (Oxford, England : 1990) 2002;38(15):2041-7.
2002: Jacoba van der Zee; Peter C M Koper; Ludy C H W Lutgens; Curt W Burger
Treatment of cervical cancer.
Lancet 2002;359(9303):357; author reply 358.
2002: Jacoba van der Zee; Peter C M Koper; Ludy C H W Lutgens; C W Burger
Point-counterpoint: what is the optimal trial design to test hyperthermia for carcinoma of the cervix? Point: addition of hyperthermia or cisplatin to radiotherapy for patients with cervical cancer; two promising combinations--no definite conclusions.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2002;18(1):19-24.
2001: Carien L Creutzberg; Wim L J van Putten; Peter C M Koper; Marnix L M Lybeert; Jan J Jobsen; Carla C Wárlám-Rodenhuis; Karin A J De Winter; Ludy C H W Lutgens; Alfons C M van den Bergh; E van der Steen-Banasik; Henk Beerman; Mat van Lent
The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial.
International journal of radiation oncology, biology, physics 2001;51(5):1246-55.
2001: Carlo L M Marcelis; H W H M van der Putten; C Tops; Ludy C H W Lutgens; Ute Moog
Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation?
Familial cancer 2001;1(2):107-9.
2000: Carien L Creutzberg; Wim L J van Putten; Peter C M Koper; Marnix L M Lybeert; Jan J Jobsen; Carla C Wárlám-Rodenhuis; Karin A J De Winter; Ludy C H W Lutgens; Alfons C M van den Bergh; E van de Steen-Banasik; Henk Beerman; Mat van Lent
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.
Lancet 2000;355(9213):1404-11.